Curated News
By: NewsRamp Editorial Staff
November 17, 2026

Nutriband Secures USPTO Trademark Allowance for Abuse-Deterrent Fentanyl Patch

TLDR

  • Nutriband secured USPTO allowance for brand trademarks on its abuse-deterrent fentanyl patch, targeting peak U.S. sales of $80 million to $200 million.
  • Nutriband's AVERSA technology uses aversive agents in transdermal patches to deter abuse and is patented in 46 countries, with global brand submissions planned.
  • Nutriband's abuse-deterrent fentanyl patch aims to prevent misuse and accidental exposure, potentially reducing harm and improving safety for patients and communities.
  • Nutriband's naming process focuses on minimizing medication errors from similar-sounding drug names, and its AVERSA technology could be applied to any transdermal patch.

Impact - Why it Matters

This news matters because it signals progress in addressing the opioid crisis through innovative abuse-deterrent technology. Nutriband’s AVERSA™ technology could reduce misuse and accidental exposure to fentanyl, a potent opioid driving overdose deaths. The trademark allowance and planned global brand name submission to regulators are critical steps toward commercialization, potentially bringing a safer fentanyl patch to market. With estimated peak U.S. sales of $80-$200 million, the product could also offer significant revenue potential for the company and its investors. Moreover, the international patent coverage and regulatory strategy underscore the global need for such solutions, impacting public health and safety beyond the U.S.

Summary

Nutriband (NASDAQ: NTRB) has received a Notice of Allowance from the USPTO for trademarks tied to its lead abuse-deterrent fentanyl transdermal system. The company plans to pursue full registration in the U.S. and internationally, and is preparing to submit its proposed global brand name to the FDA, EMA, and other regulators for preapproval review. Nutriband emphasizes that its naming process aims to minimize medication errors from similar-looking or similar-sounding drug names. The lead product uses the proprietary AVERSA™ technology, designed to deter abuse and misuse of fentanyl patches while reducing accidental exposure. Nutriband estimates peak annual U.S. sales of $80 million to $200 million and is pursuing international markets. AVERSA incorporates aversive agents into transdermal patches to discourage misuse of drugs with abuse potential, including opioids and stimulants, and is backed by patents in 46 countries.

For full details, visit https://ibn.fm/FN3Or. Nutriband Inc. focuses on developing transdermal pharmaceutical products, with its lead asset being the abuse-deterrent fentanyl patch. The company’s website is www.nutriband.com. The news was distributed by BioMedWire, a communications platform specializing in biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, offering wire solutions, editorial syndication, press release enhancement, social media distribution, and corporate communications. This infrastructure supports companies in reaching investors and the public effectively.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband Secures USPTO Trademark Allowance for Abuse-Deterrent Fentanyl Patch

Blockchain registration record for this content